ClinicalTrials.gg
CompletedNCT03093701Updated Dec 23, 2021Results posted

TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

A Phase 2 interventional study of TLC399 (ProDex) in Retinal Vein Occlusion and Macula Edema, sponsored by Taiwan Liposome Company. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-23.

Sponsored by Taiwan Liposome Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies in Retinal Vein Occlusion with a site in United States — 6 open to participants now, 10 under way, 1 of them phase 3. Retinal Vein Occlusion · United States.

Enrollment
52nd of 90
31 · median 40
Started
2017
with 2 others
Phase 2
16 of 106
1 open now
Registered
71st of 106
by date

Among the 106 studies in Retinal Vein Occlusion with a site in United States, this one is the 52nd largest by enrollment of the 90 interventional ones that give a count, is one of 3 that started in 2017, is one of 16 in phase 2, and was the 71st registered.

Retinal Vein Occlusion

289 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.

Browse Retinal Vein Occlusion studies →

Open to participants now

6 of the 106 studies in Retinal Vein Occlusion with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Retinal Vein Occlusion with a site in United States, or all of them as a file.
02

Study summary

Randomized, double-masked trial designed to investigate the use of TLC399 (ProDex) in subjects with macular edema due to CRVO or BRVO.

Read the detailed description

Part 1 is a randomized, double-maskedtrial trial designed to investigate the use of TLC399 in subjects with macular edema due to CRVO or BRVO. Three different dose strengths will be evaluated.

Part 2 is a randomized, double-masked study designed to evaluate 2 doses of TLC399 in subjects with macular edema due to CRVO or BRVO. Subjects will be randomized 1:1 to receive two different dose strenghs of investigational product.

03

Conditions studied

  • Retinal Vein Occlusion
  • Macula Edema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. male or female, at least 18 years of age
  2. macular edema due to CRVO or BRVO
  3. best-corrected visual acuity (BCVA) score of 20/40 to 20/400
  4. mean central subfield thickness (CST) ≥350 um
  5. willing and able to comply with the study procedure and sign a written
  6. agree to use a medically acceptable form of

Exclusion criteria

Exclusion Criteria:

  1. poorly controlled diabetes
  2. history of significant intraocular pressure (IOP) elevation to treatment
  3. history of ocular hypertension and glaucoma
  4. cataract surgery in the study eye within 3 months, or intraocular surgery within 6 months prior to screening
  5. use of hemodilution for the treatment of RVO
  6. use of IVT ranibizumab or bevacizumab in the study eye within 6 weeks prior to screening; or IVT aflibercept within 8 weeks prior to screening
  7. IVT Ozurdex to the study eye within 6 months prior to screening
  8. prior use of Retisert or Iluvien
  9. use of systemic steroids or heparin within 1 month prior to screening
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Group 1

    TLC399 (ProDex) 0.36mg DSP with 100 mM PL

    Drug: TLC399 (ProDex)

  • Experimental
    Group 2

    TLC399 (ProDex) 0.6 mg DSP with 100 mM PL

    Drug: TLC399 (ProDex)

  • Experimental
    Group 3

    TLC399 (ProDex) 0.6 mg DSP with 50 mM PL

    Drug: TLC399 (ProDex)

  • Experimental
    Group 4

    TLC399 (ProDex) 0.84 mg DSP with 50 mM PL

    Drug: TLC399 (ProDex)

Interventions

  • 2-vial system: TLC399-DSP and TLC399-Lipid

    Also known as: TLC399

06

What researchers measure

Primary outcomes

  1. Proportion of Subjects With BCVA Gain of 15 or More Letters From Baseline in the Study Eye

    Proportion of subjects with BCVA gain of 15 or more letters from baseline in the study eye. Patients who received rescue medication/procedures within 6 months after the study treatment was initiated were considered failure to achieve a gain of at least 15 BCVA letters.

    Time frame: 6 months after dosing

07

Results

Posted Dec 23, 2021

Participant flow

Participant flow — Overall Study
MilestoneGroup 1Group 2Group 3Group 4
Started1010110
Completed107110
Not completed0300

Outcome measures

PrimaryProportion of Subjects With BCVA Gain of 15 or More Letters From Baseline in the Study Eye

Proportion of subjects with BCVA gain of 15 or more letters from baseline in the study eye. Patients who received rescue medication/procedures within 6 months after the study treatment was initiated were considered failure to achieve a gain of at least 15 BCVA letters.

Time frame:
6 months after dosing
Reported as:
Count of participants · Participants
Proportion of Subjects With BCVA Gain of 15 or More Letters From Baseline in the Study Eye
ParticipantsGroup 1Group 2Group 3
Proportion of Subjects With BCVA Gain of 15 or More Letters From Baseline in the Study Eye111

Adverse events

Collected over 14 days (screening) + 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 10/10 (0%)0/10 (0%)10/10 (100%)
Group 20/8 (0%)2/8 (25%)8/8 (100%)
Group 30/13 (0%)1/13 (7.7%)13/13 (100%)
Most frequent serious events
Most frequent serious events
EventGroup 1Group 2Group 3
Vitreous hazeEye disorders0/101/80/13
Vitreous haze leading to significant vision lossEye disorders0/101/80/13
Transient ischaemic attackNervous system disorders0/100/81/13
PneumoniaInfections and infestations0/100/81/13
Acute colitiGastrointestinal disorders0/100/81/13
Pericardial effusionCardiac disorders0/100/81/13
Most frequent other events
Showing 10 of 80
Most frequent other events
EventGroup 1Group 2Group 3
Vitreous hazeEye disorders10/108/813/13
Visual acuity reducedEye disorders4/104/81/13
Macular oedemaEye disorders4/102/85/13
Conjunctival haemorrhageEye disorders4/102/81/13
Intraocular pressure increasedInvestigations2/103/84/13
Vision blurredEye disorders3/101/81/13
Vitreous floatersEye disorders2/102/82/13
Vitrous detachmentEye disorders0/102/80/13
HypertensionVascular disorders1/101/83/13
NasopharyngitisInfections and infestations2/100/81/13

Baseline characteristics

Baseline analysis population was based on mITT population, which was defined as subjects who had at least 1 post-treatment efficacy evaluation

Age, Continuous
Age, Continuous(years)Group 1Group 2Group 3Total
Mean72.1 ± 10.4063.5 ± 12.5568.5 ± 8.2068.1 ± 10.70
Sex: Female, Male
Sex: Female, Male(Participants)Group 1Group 2Group 3Total
Female3418
Male761023
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1Group 2Group 3Total
Hispanic or Latino2327
Not Hispanic or Latino87823
Unknown or Not Reported0011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1Group 2Group 3Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0011
Black or African American1113
White99927
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Group 1Group 2Group 3Total
United States10101131
RVO Type
RVO Type(Participants)Group 1Group 2Group 3Total
BRVO76720
CRVO34411
CST (study eye)
CST (study eye)(µm)Group 1Group 2Group 3Total
Mean530.6 ± 133.56776.9 ± 288.67702.1 ± 195.15670.9 ± 231.75
BCVA (study eye)
BCVA (study eye)(letters)Group 1Group 2Group 3Total
Mean61.5 ± 7.4048.2 ± 16.9451.1 ± 16.6653.5 ± 15.10

1 further baseline measures are reported on the registry.

08

Study locations

20 sites
  • Retinal Research Institute
    Phoenix, Arizona 85014, United States
  • Retina Institute of California
    Arcadia, California 91007, United States
  • Retina-Vitreous Associates Medical Group
    Beverly Hills, California 90211, United States
  • Retina Institute of California
    Palm Desert, California 92260, United States
  • Colorado Retina Associates
    Golden, Colorado 80401, United States
  • Retina Group of New England
    New London, Connecticut 09320, United States
  • Retina Macula Specialists of Miami
    Miami, Florida 33126, United States
  • Georgia Retina, P.C
    Marietta, Georgia 30060, United States
  • Ophthalmic Consultants of Boston
    Boston, Massachusetts 02114, United States
  • Retina Consultants of Nevada
    Las Vegas, Nevada 89149, United States
  • Retina Associates of Western New York, PC
    Rochester, New York 14620, United States
  • Charlotte Eye Ear Nose & Throat Assoc, PA
    Charlotte, North Carolina 28210, United States
  • The Cleveland Clinic
    Cleveland, Ohio 44915, United States
  • Retina Research Institute of Texas
    Abilene, Texas 79606, United States
  • Retina Research Center
    Austin, Texas 78705, United States
  • Retina Consultants of Houston
    Houston, Texas 77030, United States
  • Medical Center Ophthalmology Associates
    San Antonio, Texas 78240, United States
  • Retinal Consultants of San Antonio
    San Antonio, Texas 78240, United States
  • Retina Consultants of Houston,The Woodlands
    The Woodlands, Texas 77384, United States
  • University of Virginia
    Charlottesville, Virginia 22903, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Feb 2019, 22 months.

Results were first posted in Dec 2021, 2 years 10 months after primary completion.

Of 14 phase 2 interventional studies under Retinal Vein Occlusion, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 29. This study's 22 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2017
First posted
Mar 28, 2017
StartActual
Apr 1, 2017
Primary completionActual
Feb 4, 2019
CompletionActual
Feb 4, 2019
Results first posted
Dec 23, 2021
Last update
Dec 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03093701
Lead sponsor
Taiwan Liposome Company
Responsible party
Sponsor
First posted
Mar 28, 2017
Start date
Apr 1, 2017
Primary completion
Feb 4, 2019
Completion
Feb 4, 2019
Results posted
Dec 23, 2021
Last update
Dec 23, 2021

Study contacts

Yvonne Shih
study director · Taiwan Liposome Company, Ltd.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone phosphate

Start the discussion